The European Charcot-Marie-Tooth Federation (ECMTF) highlights a pivotal step forward in the pursuit of effective treatments for Charcot-Marie-Tooth disease (CMT). A collaborative coalition of patient advocacy groups, clinicians, and pharmaceutical representatives has formulated a new consensus on therapeutic development. Originally intended to be an FDA Guidance Document, it was instead reformatted and submitted for publication in a leading peer reviewed journal for the peripheral neuropathy field (JPNS).This framework provides clear expectations for trial design, meaningful patient outcomes, and regulatory pathways to accelerate the delivery of life-changing therapies to the CMT community.
The Urgent Need for Modern Clinical Trials
The necessity for modernized trial designs is underscored by recent setbacks in the CMT clinical landscape, where therapies missed primary endpoints despite demonstrating potential benefits or strong safety profiles. For instance, the Phase 3 PREMIER trial for Pharnext’s PXT3003 (targeting CMT1A) failed to show a statistically significant improvement on its primary endpoint, the Overall Neuropathy Limitations Scale (ONLS), a result complicated by unexpected improvements in the placebo group. Similarly, in early 2026, NMD Pharma’s Phase 2a SYNAPSE-CMT trial for ignaseclant missed its primary endpoint on the 6-minute walk test, even though secondary endpoints revealed promising, clinically meaningful improvements. These outcomes illustrate the profound difficulties of measuring efficacy in a slowly progressive, rare disease using conventional metrics.
New Recommendations for Trial Design
To address these hurdles, the new guidelines offer comprehensive recommendations to provide drug developers with a predictable, patient-focused roadmap.
Flexible Frameworks and Broad Inclusion
Traditional randomized placebo-controlled trials can be burdensome for patients with progressive conditions. The framework supports adaptive strategies, single-participant designs, and the use of external controls when scientifically justified to minimize placebo exposure. Furthermore, because many CMT variants share a similar clinical progression, trials should consider broad inclusion criteria based on shared physical presentations rather than restricting participation solely by genetic subtype. This approach can speed up enrollment and broaden the applicability of potential treatments.
Meaningful Endpoints and Biomarkers
Measuring success requires tools that accurately capture the functional reality of patients. Trials must utilize validated, disease-specific clinical outcome assessments and patient-reported outcomes capable of detecting functional changes across varying disease stages to avoid floor or ceiling effects. Additionally, the integration of biomarkers, such as MRI-based muscle fat fraction or neurofilament light chain, can reliably reflect peripheral nervous system health, guide dose selection, and potentially serve as surrogate endpoints for accelerated regulatory approval.
Early Intervention and Patient-Centricity
Because therapeutic benefit is often highest before irreversible muscle and axonal damage occurs, the recommendations strongly support initiating trials in younger populations as early as ethically and scientifically appropriate. Throughout this process, clinical development must align with what patients and care partners define as meaningful improvements. The framework emphasizes that patient risk tolerance may increase given the serious nature of the disease and the high unmet medical need.
Accessing the Full Publication
The complete consensus framework, titled “Clinical Development of Therapies for Charcot-Marie-Tooth Disease: Recommendations for Trial Design, Endpoints, and Regulatory Pathways,” is published in the Journal of the Peripheral Nervous System.
